This is to inform that due to some circumstances beyond the organizer control, “International Conference on Medicinal Chemistry, Computer Aided Drug Design and Delivery” (MCADD 2023) Hybrid event during September 14-16, 2023 at Valencia, Spain has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at medicinal-chemistry@magnusconference.com or call + 1 (702) 988 2320.
Increased mammalian tumour recurrence and severe chemotherapeutic agent side effects limit the clinical efficacy of a wide range of anticancer drugs now in use. As a result, developing alternative or synergistic anticancer medications with low side effects is constantly a priority. Anticancer drugs obtained from natural sources are one major technique for developing effective anticancer medicines. Plant-based anticancer agents and their derivatives have been shown to be useful in the prevention and treatment of cancer. Most anticancer drugs have a limited therapeutic index and a strong dose response relationship. Small dose fluctuations can cause severe and life-threatening toxicity in some people and underdosing in others, thereby compromising cancer results. Particularly in those with potentially curable conditions like lymphoma or testicular cancer, and in the context of adjuvant treatment, proper dose selection is critical (e.g., breast and colon cancer). The fact that everyone's capacity to metabolise and remove medications varies greatly complicates finding the optimum dose.
Title : A qsar survey on tyrosine kinase inhibitors
Atefeh Hajiagha Bozorgi, Faculty of pharmacy, Iran (Islamic Republic of)
Title : Abbott diagnostics: COVID-19 inactivation, nucleocapsid antigen automated immunoassay development, and variant testing for automated and lateral flow assays binaxnow™ and panbio™
Philip M Hemken, Abbott Laboratories, United States
Title : Synthesis, antibacterial activity of 3-amino 5-methoxyl-2-methyl quinazolin-4(3H)-one an amino-6-methoxyl-2-methyl of 4H–benzo[d] [1,3]–oxazine–4–one
Osarumwense Peter Osarodion, Ondo State University of Sciences and Technology, Nigeria
Title : Tackling mycobacterium tuberculosis resistance with tailored isatin-pyrimidine hybrids enoyl acyl carrier protein reductase (Inha)
Amgad Albohy, The British University in Egypt (BUE), Egypt
Title : Transition metal complexes/Organometallic compounfs as anticancer drugs
Prakash kinthda, Nims university,jaipur,rajasthan, India
Title : New n-ribosides and n-mannosides of rhodanine derivatives with anticancer activity on leukaemia cell line: Design, synthesis, dft and molecular modelling studies
Ahmed, Kafrelsheikh University, Egypt